Nguyen AnhCo, the President and CEO of Atara Biotherapeutics, Inc. (NASDAQ:ATRA), has reported the sale of 1,664 shares of common stock. The transaction, which took place on November 18, 2024, was ...
Atara is working closely with its partners and the FDA to lift clinical hold and support EBVALLO ™ BLA resubmission in the U.S. Atara remains focused on delivering on the future financial value of ...
Atara Biotherapeutics sees European approval for tab-cel, signaling potential in oncology and autoimmune diseases, despite US regulatory hurdles. Recent financials show decreased losses, reduced ...
The latest price target for Atara Biotherapeutics (NASDAQ:ATRA) was reported by Canaccord Genuity on March 11, 2025. The analyst firm set a price target for $17.00 expecting ATRA to rise to within 12 ...
Atara Biotherapeutics (ATRA) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $0.96 per share a year ago. These ...
Company to Further Analyze Data and Evaluate Strategic Options for ATA188 Program with Focusing of Resources and Planned Expense Reductions Expected to Extend Cash Runway Beyond Q3 2025 Allogeneic CAR ...
Atara Biotherapeutics Inc. (ATRA) announced Greg Ciongoli will serve as chair of the board of directors, according to a company... Director James Huang of Atara Biotherapeutics, Inc. (NASDAQ: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback